{"id":40041,"date":"2021-02-24T07:24:18","date_gmt":"2021-02-24T07:24:18","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40041"},"modified":"2021-02-26T16:33:09","modified_gmt":"2021-02-26T16:33:09","slug":"unprecedented-rapid-speed-of-covid-vaccine-development","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40041","title":{"rendered":"Unprecedented rapid speed of COVID vaccine development"},"content":{"rendered":"<p><b><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" width=\"231\" height=\"142\" \/><\/span><\/strong>Simon\u00a0Collins,\u00a0HIV\u00a0i-Base<\/b><\/p>\n<p><strong>Although HTB mainly includes reports with immediate clinical significance, a paper recently published in Annals of Internal Medicine is interesting for highlighting the unusually rapid development of vaccines against COVID-19.<\/strong><\/p>\n<p>Hopefully this sets a benchmark for future research.<\/p>\n<p>A literature search, principally of studies listed on ClinicalTrials.gov, traced the likelihood of candidate vaccines for 23 new or emerging viral infections progressing from phase 2 to FDA approval and the associated timelines since 2005.<\/p>\n<p>From 606 trials (involving 220 candidate vaccines and 267,000 participants) the probability of vaccines being approved within 10 years was 10% (95%CI: 2.6 to 16.9) with median time of 4.4 years (95%CI: 6.4 to 13.9). Most vaccines were against H1N1 or H5N1.<\/p>\n<p>The study also concluded that any COVID vaccine developed within 18 months of phase 2 would be unprecedented.<\/p>\n<p>Reference<\/p>\n<p>MacPherson A et al.\u00a0Probability of success and timelines for the development of vaccines for emerging and reemerged viral infectious diseases.\u00a0Ann Intern Med.\u00a0[Epub ahead of print].\u00a0doi:10.7326\/M20-5350. (24 November 2020).<br \/>\n<a href=\"https:\/\/www.acpjournals.org\/doi\/10.7326\/M20-5350\">https:\/\/www.acpjournals.org\/doi\/10.7326\/M20-5350<\/a><br \/>\n<a href=\"https:\/\/www.acpjournals.org\/doi\/abs\/10.7326\/M20-5350\">https:\/\/www.acpjournals.org\/doi\/abs\/10.7326\/M20-5350<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon\u00a0Collins,\u00a0HIV\u00a0i-Base Although HTB mainly includes reports with immediate clinical significance, a paper recently published in Annals of Internal Medicine is interesting for highlighting the unusually rapid development of vaccines against COVID-19. Hopefully this sets a benchmark for future research. A &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-40041","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40041"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40041\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}